Kiniksa to present data for KPL-716 at EADV
Kiniksa announced that it will present clinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta, or OSMRss, at the 27th European Academy of Dermatology and Venereology, or EADV. Zamaneh Mikhak of Kiniksa will deliver an oral presentation of the company's placebo-controlled, double-blind, single-ascending-dose, Phase 1a/1b clinical trial of KPL-716. This clinical trial evaluated the safety, tolerability, pharmacokinetics and immunogenicity of intravenous or subcutaneous KPL-716 in healthy volunteers and subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus. Atopic dermatitis served as a proxy for IL-31-driven pruritic diseases as a means to assess target engagement and a potential early signal of efficacy in reducing pruritus.